Sichuan Biokin and Bristol-Myers Squibb Activate $800 Million ADC Licensing Deal
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has officially activated its licensing and cooperation agreement...
Simnova Secures RMB 200 Million in Series A+ Funding to Advance CAR Therapy Pipeline
Simnova, a Shenzhen-based developer of chimeric antigen receptor (CAR) adoptive cell therapies, has successfully raised...
ClouDr Launches Dapagliflozin, Generic Version of AstraZeneca’s Forxiga, After NMPA Approval
Hangzhou Kang Ming Information Technology Co., Ltd. (HKG: 9955), known as “ClouDr,” has officially launched...
BeiGene Launches Legal Action Against Sandoz and MSN Over Brukinsa Patent Infringement
BeiGene Ltd. (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has initiated patent...
Eli Lilly Delays Donanemab Action Date as FDA Calls for Advisory Committee Review
Eli Lilly (NYSE: LLY) has announced a delay in the action date for its Alzheimer’s...
China Cracks Down on Medical Insurance Fraud with New Guidelines and Increased Prosecutions
China’s Supreme People’s Court, along with the Supreme People’s Procuratorate and the Ministry of Public...
FDA Approves Wegovy for Cardiovascular Risk Reduction in Obese Patients, First of Its Kind
The U.S. Food and Drug Administration (FDA) granted an indication extension approval last week to...
Amgen Reports Positive Results for Otezla in Pediatric Psoriasis Trial
Amgen (NASDAQ: AMGN) provided an update last week on a late-stage trial evaluating its PDE4...
Merck’s 2023 Annual Report: A Mixed Bag Amid Global Challenges
Merck KGaA (ETR: MRK), a leading German chemical, reported a 5.6% decline in its global...
GSK Reports US Adult Non-Flu Vaccination Rates Recover Post-Pandemic
GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reported that...
BMS’s Opdivo Secures FDA Approval for First-Line Urothelial Carcinoma Treatment
The US Food and Drug Administration (FDA) has granted Bristol Myers Squibb (BMS; NYSE: BMY)...
BeiGene’s Brukinsa Receives FDA Approval for Relapsed or Refractory Follicular Lymphoma
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biotech company based in China,...
Visen Pharmaceuticals’ TransCon hGH Accepted for Review by China’s NMPA
Visen Pharmaceuticals, a joint venture between Denmark-based Ascendis Pharma and Chinese healthcare-focused investment firm Vivo...
Shandong Luoxin Pharmaceutical Partners with Xbiome to Access Microbiome Transplantation Technology
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a pharmaceutical company based in China,...
Shanghai Fosun Pharma Gets NMPA Green Light for Universal NK Cell Therapy GCK-01 Clinical Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Novo Nordisk’s Anti-Obesity Drug Wegovy Eyed for China Launch in 2024
Novo Nordisk (NYSE: NVO), a leading diabetes company based in Denmark, has reportedly informed investors...
China Grand Pharmaceutical Receives FDA Approval for Post-Surgical Ophthalmic Drug GPN00833
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...
Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...
Everest Medicines to Establish Integrated Kidney Disease Diagnosis and Treatment Ecosystem
Everest Medicines (HKG: 1952), a Chinese pharmaceutical company, is set to collaborate with partners to...
Boehringer Ingelheim’s Spevigo Receives NMPA Approval for GPP Treatment in China
German pharmaceutical giant Boehringer Ingelheim (BI) has announced that it has received marketing approval from...